Increased Variability of Genomic Transcription in Schizophrenia

Fuquan Zhang1,*, Yin Yao Shugart2,*, Weihua Yue3,4,*, Zaohuo Cheng1, Guoqiang Wang1, Zhenhe Zhou1, Chunhui Jin1, Jianmin Yuan1, Sha Liu5 & Yong Xu5

Schizophrenia (SZ) is a severe chronic mental disorder with a high heritability. Current microarray analyses typically focus on identifying differentially expressed genes or enriched pathways relevant to phenotypes. Whether there is a variability change of the genomic transcription in diseases has rarely been explored. In this study, we compared coefficient of variation (CV, the ratio of the standard deviation to the mean) of genome transcription of early-onset SZ (EOS) patients with controls in a blood mRNA microarray dataset and a blood microRNA (miRNA) microarray dataset. Furthermore, we compared CV of the expression levels of 17 genes in blood of the 30 patients before and after the 12-week treatment using real-time quantitative PCR (RT-qPCR) analysis. Our results indicated a significant increase of CV of genome transcription in patients compared with controls in both the mRNA and the miRNA datasets. The 30 after-treatment patients showed a significant decrease of CV of gene expression compared with the before-treatment patients. Our study may implicate the blood gene expression variability in SZ, providing further evidence supporting the abnormality of peripheral blood transcriptome in SZ. Given that peripheral blood can be easily collected from patients and followed longitudinally, our results may indicate a new way to facilitate the identification of the signatures of clinical subtypes, their prognosis and treatment response.

Schizophrenia (SZ) is a severe chronic mental disorder with a high heritability. It profoundly disrupts such key traits of human cognition and personality. SZ patients tend to first present with overt symptoms during late adolescence or early adulthood. When the disease manifests before age 18, it is categorized as early-onset SZ (EOS), a subcategory of SZ associated with more familial vulnerability and poor outcomes1.

It has been hypothesized that the gene expression is the most fundamental level at which the genotypes critically influence the SZ phenotypes. Peripheral blood mononuclear cells (PBMCs) can be easily collected from patients and followed longitudinally with gene expression analyses, providing a way of identifying the signatures of clinical subtypes, their prognosis and treatment response. Microarray-based gene expression profiling has been used to explore peripheral molecular disruption in SZ patients. Current microarray analyses typically focus on identifying differentially expressed genes or enriched pathways in different phenotypes. Whether there is a variability change of the genomic transcription in diseases has rarely been explored. In this study, we aim to investigate the possible change of genome expression variability in SZ. We used the coefficient of variation (CV) as a measure to evaluate the magnitude of genome expression variability. CV, the ratio of the standard deviation, is a standardized measure of dispersion of a probability distribution or frequency distribution.

Results
We compared the CV of genome transcription of SZ patients with controls in two microarray datasets. In the mRNA dataset, there was a 38.71% increase of CV of genome transcription in patients compared with controls 19.75% ($P < 1.00E-30$); while in the mRNA dataset, there was a 19.75% increase of CV of miRNA expression in the patients compared with controls ($P = 3.30E-30$, Table 1, Fig. 1).

Received: 11 August 2015
Accepted: 10 November 2015
Published: 10 December 2015

1Wuxi Mental Health Center, Nanjing Medical University, Wuxi, Jiangsu Province, China . 2Unit on Statistical Genomics, Division of Intramural Research Program, National Institute of Mental Health, Bethesda, Maryland, United States of America. 3Institute of Mental Health, Sixth Hospital, Peking University; Beijing 100191, China. 4Key Laboratory of Mental Health, Ministry of Health & National Clinical Research Center for Mental Disorders (Peking University), Beijing, 100191, China. 5Department of Psychiatry, First Hospital /First Clinical Medical College of Shanxi Medical University, Taiyuan, China. *These authors contributed equally to this work. Correspondence and requests for materials should be addressed to F.Z. (email: zhangfq@njmu.edu.cn) or Y.X. (email: xuyongsmu@vip.163.com)
We compared CV of expression levels of the 17 genes in the patients before and after the treatment using RT-qPCR analysis. After the treatment, the 30 patients showed a significant decrease of CV of expression levels of the 17 genes (16.05%, \(P = 0.015\), Table 2). However, there were no significant changes of expression levels for each of the 17 genes after the treatment (Table 3).

### Discussion

The transcriptome sits between environmental influence and the genetic susceptibility to SZ and thus may serve as a bridge between certain endophenotypes and the genetic changes that lead to the disorder. Unlike the most of the previous expression studies, we focus on alterations of expression variability in SZ patients.

Changes of gene expression variability have been observed in different biological conditions or phenotypes\(^2,3\). Our findings support the increased genome expression variability in drug-free SZ patients. Strikingly, the magnitude of the changes was relative large, with a nearly 40% and 20% increase of CV in mRNA and miRNA profiles, respectively. The increased CV may reveal a more irregular expression pattern in SZ compared with controls, plausibly resulting from the stochastic deregulation of the genome expression\(^4,5\).

miRNAs are a class of vital gene expression regulators posttranscriptionally repress expression of target genes by mRNA degradation or translational inhibition. Our miRNA microarray dataset indicated a down-regulation and an increased variance of expression levels in SZ patients, both of which may contribute to genome dysregulation.

### Table 1. Coefficient of variation of transcriptions in SZ patients and controls.

| Platform | Features | Samples | Control | SZ | Change rate | P       |
|----------|----------|---------|---------|----|-------------|---------|
| Microarray | 17,199 mRNA probes | 18 SZ/12 controls | 0.062 ± 0.043 | 0.086 ± 0.054 | 38.71% | <100E-30 |
| Microarray | 2,967 mRNA probes | 15 SZ/15 controls | 0.81 ± 0.41 | 0.97 ± 0.60 | 19.75% | 330E-30 |

### Table 2. Coefficient of variation of transcriptions in SZ patients before and after the treatment. SZ_0W: SZ patients before treatment; SZ_12W: SZ patients after 12-week treatment.

| Platform | Features | Samples | SZ_0W | SZ_12W | Change rate | P     |
|----------|----------|---------|-------|--------|-------------|-------|
| RT-qPCR  | 17 mRNAs | 30 SZ patients | 0.81 ± 0.52 | 0.68 ± 0.47 | −16.05% | 0.015 |

Figure 1. Density curves of expression CV in SZ patients and controls. The vertical dashed lines indicate mean values. (A) Density curves of mRNA expression CV in SZ patients and controls. (B) Density curves of miRNA expression CV in SZ patients and controls.

Figure 2. Platform features and samples for each platform.

Platform | Features | Samples | SZ_0W | SZ_12W | Change rate | P     |
|----------|----------|---------|-------|--------|-------------|-------|
| RT-qPCR  | 17 mRNAs | 30 SZ patients | 0.81 ± 0.52 | 0.68 ± 0.47 | −16.05% | 0.015 |
Table 3. Expression levels of in the 30 SZ patients before and after the treatment. FC: fold change.

| Gene | SZ (n = 30) | SZ_12w (n = 30) | FC | P  | FDR |
|------|-------------|-----------------|----|----|-----|
| AKT1 | 0.076 ± 0.022 | 0.071 ± 0.017 | 1.00 | 0.62 | 0.81 |
| BRCA1 | 6.57E-3 ± 2.79E-3 | 5.43E-3 ± 1.85E-3 | 1.00 | 0.15 | 0.38 |
| CCDC134 | 0.012 ± 0.026 | 2.11E-3 ± 2.95E-3 | 0.99 | 0.013 | 0.11 |
| FAMH | 4.84E-3 ± 2.25E-3 | 5.45E-3 ± 2.45E-3 | 1.00 | 0.21 | 0.44 |
| FOS | 1.09 ± 0.55 | 1.29 ± 0.84 | 1.38 | 0.47 | 0.66 |
| HTR4 | 1.70E-4 ± 9.44E-5 | 1.52E-4 ± 8.85E-5 | 1.00 | 0.45 | 0.66 |
| JUN | 4.49E-3 ± 3.60E-3 | 3.83E-3 ± 2.04E-3 | 1.00 | 0.92 | 0.98 |
| MYOD1 | 2.22E-3 ± 3.00E-3 | 1.00E-3 ± 1.87E-3 | 1.00 | 0.011 | 0.11 |
| NFKAPL | 3.40E-3 ± 2.20E-3 | 2.45E-3 ± 1.12E-3 | 1.00 | 0.085 | 0.29 |
| RGS2 | 0.75 ± 0.43 | 0.69 ± 0.28 | 0.93 | 0.98 | 0.98 |
| STAT3 | 0.049 ± 0.031 | 0.053 ± 0.027 | 1.00 | 0.25 | 0.48 |
| UBD | 3.82E-3 ± 4.70E-3 | 1.68E-3 ± 1.63E-3 | 1.00 | 0.033 | 0.14 |
| VDR | 0.018 ± 4.81E-3 | 8.95E-3 ± 1.97E-3 | 1.00 | 0.73 | 0.89 |
| ZIC2 | 3.97E-3 ± 6.36E-3 | 8.78E-4 ± 1.27E-3 | 1.00 | 0.027 | 0.14 |
| EGR1 | 0.19 ± 0.21 | 0.20 ± 0.15 | 1.00 | 0.19 | 0.44 |
| SKIL | 5.28E-3 ± 2.02E-3 | 5.57E-3 ± 1.70E-3 | 1.00 | 0.39 | 0.66 |
| NFKB | 0.026 ± 0.012 | 0.026 ± 9.44E-3 | 1.00 | 0.97 | 0.98 |

Interestingly, although none of the 17 genes showed significant changes after the treatment, collectively, their expression variances significantly decreased after the treatment, consistent with the hypothesis that biologically relevant genes can have differential variability without differential expression. The reduction of CV after the treatment further supports the relevance of CV of gene expression in SZ. To the best of our knowledge, this is the first time that trait- and treatment-related CV changes of transcripts in SZ patients were reported.

The limitation of our study might be the relative small sample size in the two microarray datasets. However, one can argue that the large number of features (genes or miRNAs) and the employing of multiple datasets may compensate this limitation. A caveat in mind was that our results were derived from peripheral blood; thus, due care should be taken when extrapolating these results into the brain of SZ patients. The strength of our study was the enrollment of drug-free patients and the relative good match of the two groups of subjects in gender and age. We are aware of the fact that expression variability may result from other sources, such as some level of heterogeneity related to sample collection. However, it is interesting to see that our experiments revealed the striking differential variability in the patients with the consistency across all the datasets.

In summary, our study indicated the increase of gene expression variability in blood of SZ patients, providing evidence supporting the alteration of peripheral blood transcriptome in the disease.

**Methods**

**Subjects.** All participants were unrelated Han Chinese recruited from the north of China. Consensus diagnoses were made by at least two experienced psychiatrists independently according to the Diagnosis and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria for SZ. Patients with unanimous diagnosis were enrolled into the study.

For the real-time RT-qPCR analysis, we enrolled 38 SZ patients who were drug-free for at least one month before the enrollment; among them 30 patients (14 males and 16 females, aged 34.5 ± 11.0 years) were successfully followed-up with a 12-week period of antipsychotic treatment (see Supplementary File for detailed information). The clinical effects were assessed by trained and experienced psychiatrists with the Positive and Negative Syndrome Scale (PANSS) respectively before and after 12-week treatment. All patients showed clinical improvement according to the PANSS reductive ratio more than 25%. All patients participating in the study were treated with one of the oral second generation or atypical antipsychotics (SGA) and tracked for 12-week continuous medication after follow-up with a 12-week period of antipsychotic treatment (see Supplementary File for detailed information).

The study was approved by Medical Research Ethics Committee of Shanxi Medical University, and all experiments were performed in accordance with the approved guidelines and regulations. Informed consent was signed by both the teenage participants and their parents or care takers.

**The mRNA microarray dataset.** The blood-based mRNA microarray dataset involves 17199 probes with valid values from 18 first-onset SZ patients (8 males and 10 females, aged 14.78 ± 1.70 years ranging from 10–18 years) and 30 healthy controls (17 males and 31 females, aged 31.6 ± 6.88 years) the blood-based mRNA microarray dataset involves 17199 probes with valid values from 18 first-onset SZ patients (8 males and 10 females, aged 14.78 ± 1.70 years ranging from 10–18 years).
years) and 12 healthy controls (6 males and 6 females, aged 14.75 ± 2.14 years ranging from 10–17 years) (NCBI GEO: GSE54913, see Supplementary File for detailed information on data processing).

The miRNA microarray dataset.  The blood-based miRNA microarray dataset involves 2967 non-missing probes from 15 first-onset SZ patients (8 males and 7 females, aged 13.80 ± 1.93 years ranging from 12–17 years) and 15 healthy controls (7 males and 8 females, aged 14.07 ± 1.82 years ranging from 9–16 years) (NCBI GEO: GSE54578, see Supplementary File for detailed information on data processing).

RT-qPCR analysis.  Total RNA was isolated from peripheral blood mononuclear cells (PBMCs) using TRIzol (Invitrogen; USA) with on-column DNase I treatment as described by the manufacturer. cDNA was synthesized using High Capacity RNA-to-cDNA Kit (Invitrogen; USA) as described by the manufacturer. The primers were listed in Supplementary Table S2. PCR was performed using a ViiA 7 Real-time PCR System (Applied Biosystems) for 10 min at 95 °C, and then 40 cycles consisting of 10 s at 95 °C, 60 s at 60 °C, 15 s at 95 °C, followed by a subsequent standard dissociation protocol to ensure that each amplicon was a single product. All quantifications were normalized to GAPDH.

Statistical analysis.  R⁸ was used to perform the data processing and analyses. Density curves were plotted with the R package ggplot2⁹. For RT-qPCR analysis, the comparative Ct (2⁻ΔΔCt) method was used for the quantification of transcripts. The differences of CV between two groups were analyzed using paired Wilcoxon rank-sum test.

References
1. Clemmensen, L., Vernal, D. L. & Steinhausen, H. C. A systematic review of the long-term outcome of early onset schizophrenia. BMC Psychiatry 12, 150 (2012).
2. Ecker, S., Pancaldi, V., Rico, D. & Valencia, A. Higher gene expression variability in the more aggressive subtype of chronic lymphocytic leukemia. Genome Med. 7, 8 (2015).
3. Eraly, S. A. Striking differences between knockout and wild-type mice in global gene expression variability. PLoS One 9, e97734 (2014).
4. Pitchard, C. C., Hsu, L., Delrow, J. & Nelson, P. S. Project normal: defining normal variance in mouse gene expression. Proc. Natl. Acad. Sci. USA 98, 13266–13271 (2001).
5. Bahar, R. et al. Increased cell-to-cell variation in gene expression in ageing mouse heart. Nature 441, 1011–1014 (2006).
6. Ho, J. W., Stefani, M., dos Remedios, C. G. & Charleston, M. A. Differential variability analysis of gene expression and its application to human diseases. Bioinformatics 24, i390–398 (2008).
7. Zhang, F. et al. Converging Evidence Implicates the Abnormal MicroRNA System in Schizophrenia. Schizophr. Bull. 41, 728–735 (2015).
8. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria, http://www.R-project.org/ (2014).
9. Wickham, H. ggplot2: elegant graphics for data analysis. Springer New York (2009).

Acknowledgements
We sincerely thank all the subjects for their support and participation and all the medical staff involved in collecting blood samples. This work was supported by the National Natural Science Foundation of China (81471364, 81271482), Beijing Natural Science Foundation (7132182), Program for New Century Excellent Talents in University (NCET-12-1036), and Construction Plan for Shanxi Science & Technology Infrastructure Platforms (2015091002-0102). Shugart was supported by the Intramural Research Program of National Institute of Mental Health, National Institutes of Health (MH002929-04).

Author Contributions
F.Z. and Y.X. designed the study; F.Z., Y.X. and Y.Y.S. did the statistical analysis and wrote the manuscript; Z.C., G.W., Z.Z., C.J., J. Y., S.L. and W.Y. contributed to administrative and material support. The views expressed in this presentation do not necessarily represent the views of the NIMH, NIH, HHS, or the United States Government.

Additional Information
Supplementary information accompanies this paper at http://www.nature.com/srep

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Zhang, F. et al. Increased Variability of Genomic Transcription in Schizophrenia. Sci. Rep. 5, 17995; doi: 10.1038/srep17995 (2015).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/